Qiuhong Li

Dr. Qiuhong Li


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in Environmental Toxicology and Pharmacology
Verified
Journal Article
Closed access
YHYang Hu
Yang Hu
LWLiu-Sheng Wang
Liu-Sheng Wang
YLYan Li
Yan Li
QLQiuhong Li
Qiuhong Li
CLChun-Lin Li
Chun-Lin Li
HLHui-Ping Li
Hui-Ping Li

1 February 2019 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
DWDong Weng
Dong Weng
QWQin Wu
Qin Wu
XCXian-Qiu Chen
Xian-Qiu Chen
YDYu-Kui Du
Yu-Kui Du
TCTao Chen
Tao Chen
HLHui-Ping Li
Hui-Ping Li
Azithromycin (AZM), that is a macrolide antibiotic, has been found to treat diffuse panbronchiolitis (DPB) effectively. However, the mechanism of action underlying the therapeutic effects remains unclear. We selected 64 patients with DPB from 305 patients who were diagnosed with DPB at the outpatient clinic in Shanghai Pulmonary Hospital from Jan 2010 to Oct 2014. The primary PBLs, CD4 + T cells, and Jurkat T cells were treated with AZM or erythromycin (EM), and the effects of AZM and EM on IL-17A and CXCL-2 production, proliferation, apoptosis and autophagy were evaluated. AZM and EM significantly inhibited IL-17A and CXCL-2 production in patients' PBLs (all P < 0.05). AZM significantly inhibited proliferation and promoted apoptosis of T cells from DPB patients. AZM can enhance autophagosome formation of T cells by suppressing S6RP phosphorylation, which is a downstream target of mTOR pathway (all P < 0.05). AZM and EM significantly decreased secreted IL-17A levels (P < 0.05) in the primary CD4 + T cells of patients with DPB. AZM may treat DPB patients by targeting cytokine production, proliferation, apoptosis and autophagy of T cell. The mechanism of therapeutic effects of AZM on DPB may be associated with a specific inhibition of mTOR pathway in the T lymphocytes.

25 October 2023 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
XHXian He
Xian He
YZYuan Zhang
Yuan Zhang
YZYing Zhou
Ying Zhou
LI LILI LI
LI LI
QLQiuhong Li
Qiuhong Li
Background: The aim of this study was to evaluate the role of Xpert MTB/RIF assay in the detection of Mycobacterium tuberculosis for differentiating tuberculosis intrathoracic lymphadenopathy from sarcoidosis intrathoracic lymphadenopathy. Methods: The patients who were suspected to having sarcoidosis or tuberculosis intrathoracic lymphadenopathy at the Shanghai Pulmonary Hospital between October 1, 2020 and June 30, 2021 were retrospectively evaluated in this study. All patients underwent endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) and Xpert analysis. Differences in clinical and radiological features were recorded. The diagnostic performances of EBUS-TBNA Xpert, acid-fast bacilli, culture, and peripheral blood QuantiFERON-TB Gold (QFT) for differentiating sarcoidosis from tuberculosis intrathoracic lymphadenopathy were analyzed. Results: A total of 119 patients were included in this analysis. Of those, 83 patients were finally diagnosed with sarcoidosis (N = 50) and tuberculosis (N = 33) intrathoracic lymphadenopathy. Young individuals were more likely to have tuberculosis versus sarcoidosis intrathoracic lymphadenopathy (P = 0.006). Markers of inflammation, including fever, leukocytes, and serum ferritin levels, were significantly higher in tuberculosis versus sarcoidosis intrathoracic lymphadenopathy (P < 0.01). Bilateral lung involvement and symmetry intrathoracic lymphadenopathy were more common in sarcoidosis intrathoracic lymphadenopathy (P < 0.01). In addition, the longest diameter of intrathoracic lymphadenopathy (in cm) was significantly larger in sarcoidosis intrathoracic lymphadenopathy (P = 0.001). However, the largest diameter of lung lesions was significantly shorter (P = 0.005). The sensitivity and specificity values of Xpert and QFT for differentiating these two diseases were 69.70% and 100%, and 96.43% and 91.84%, respectively. Conclusion: Xpert MTB/RIF is recommended for the diagnosis of tuberculosis intrathoracic lymphadenopathy using EBUS-TBNA samples. A negative QFT suggests the exclusion of the diagnosis of tuberculosis intrathoracic lymphadenopathy.

20 March 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
HYHanming Yu
Hanming Yu
MZMengmeng Zhao
Mengmeng Zhao
QLQiuhong Li
Qiuhong Li
YZYuan Zhang
Yuan Zhang
Pulmonary fibrosis (PF) significantly increases the risk of lung cancer (LC), but the mechanisms underlying this transition remain unclear. This overview positions macrophage heterogeneity as a central node within the PF-LC continuum. First, we describe important subpopulations of profibrotic and pro-tumor macrophages, including SPP1+, MERTK+, TREM2+, and MARCO+ cells, using high-resolution spatial and single-cell omics technologies. Next, we analyze the fundamental mechanisms that determine their function: the fibrotic microenvironment (e.g., extracellular matrix stiffness, hypoxia) induces profound metabolic reprogramming (e.g., Warburg effect, lipid peroxidation) and stabilizes epigenetic memory (e.g., DNA methylation, histone modifications), locking them into a pathogenic state. This reprogramming occurs through two main pathways: (1) metabolic reprogramming, characterized by aerobic glycolytic conversion and dysregulated lipid metabolism, which stimulates both pathogenic functions and suppression of T cell activity; (2) Epigenetic modifications, including stabilized alterations in DNA methylation, histone modifications, and superactivator patterns, which maintain cells in a tumor-promoting phenotype. As central nodes of communication, these macrophages interact pathologically with fibroblasts and epithelial cells through secreted factors and extracellular vesicles, forming self-reinforcing feedback loops that promote disease progression. We are studying the crucial role of new technologies, particularly multi-omic spatial models and high-precision organoids, in fostering mechanistic discoveries. These discoveries pave the way for new macrophage-focused therapeutic strategies, including the precise stratification of patients using biomarkers from liquid biopsies (such as soluble SPP1 and MARCO) and the development of targeted drug delivery systems for the selective modulation of macrophage function, thus establishing a new paradigm for therapeutic interventions in pulmonary fibrosis with concomitant lung cancer.

2 August 2025 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
DZDafu Zhu
Dafu Zhu
JCJianglong Chen
Jianglong Chen
LZLi Zhang
Li Zhang
HLHongxu Li
Hongxu Li
JWJingyi Wang
Jingyi Wang
MZMengmeng Zhao
Mengmeng Zhao
Sarcoidosis is a systemic inflammatory disease, primarily affecting the lungs, with a prognosis that varies widely among patients. While some patients recover spontaneously after diagnosis, others experience disease progression. Currently, the metabolomic profile associated with pulmonary sarcoidosis and its different clinical outcomes remains poorly understood. Serum samples from 29 pulmonary sarcoidosis patients and 10 healthy controls were analyzed using untargeted UPLC-MS/MS metabolomics. Univariate and multivariate analyses identified differentially expressed metabolites, followed by pathway enrichment to evaluate their biological relevance. Patients were further stratified into self-healing (n = 11) and progressive (n = 18) subgroups based on prognosis. Differential metabolites between subgroups were compared, potential biomarkers were selected, and their diagnostic performance assessed. Correlations with clinical parameters were also analyzed to explore associations with disease progression. Sarcoidosis patients showed distinct serum metabolic profiles compared to healthy controls, with 10 upregulated and 199 downregulated metabolites. Pathway analysis indicated enrichment in amino acid, lipid, and immune-related pathways. Between prognostic subgroups, 25 differential metabolites were identified. Uric acid, testosterone sulfate, allopregnanolone sulfate, and 24,25-dihydroxyvitamin D3 emerged as key metabolites with prognostic value and moderate correlations with clinical parameters. This study highlights distinct serum metabolic profiles associated with sarcoidosis prognosis, suggesting that specific metabolic alterations may aid in monitoring and predicting disease outcomes. These findings offer a foundation for future research into personalized treatment and management strategies.

27 July 2026 in Ecotoxicology and Environmental Safety
Verified
Journal Article
Open access
HYHanming Yu
Hanming Yu
MLMiao Li
Miao Li
XKXin Kang
Xin Kang
YDYi Dai
Yi Dai
FLFei Li
Fei Li
QLQiuhong Li
Qiuhong Li
Nitro-aromatic compounds (NACs) are pervasive environmental pollutants with recognized pulmonary toxicity, yet their mechanistic involvement in pulmonary fibrosis remains incompletely understood. We applied an integrative framework combining network toxicology, transcriptomic analysis, prognostic modeling, immune infiltration profiling, molecular docking, and molecular dynamics (MD) simulations to investigate the fibrogenic effects of two representative NACs, 1-nitropyrene (1-NP) and nitrobenzene (NB). Identification and evaluation of NACs-related targets and their clinical relevance using the idiopathic pulmonary fibrosis (IPF) GEO dataset. Network analysis using eight topological algorithms identified ten key genes occupying central positions in the NACs-associated fibrosis-related candidate network. Among these, BCL2L1 and MYC exhibit significant prognostic significance in IPF.Risk models based on hub genes effectively stratify patient survival rates and are closely associated with immune dysregulation, characterized by macrophage aggregation and CD8⁺ T cell exhaustion. Molecular docking analysis indicates that 1-NP and NB exhibit strong binding affinity with the anti-apoptotic protein BCL2L1. Notably, 100-ns MD simulations revealed that NACs binding was associated with significant conformational destabilization and partial unfolding of BCL2L1, as evidenced by sustained increases in Root mean square deviation (RMSD), radius of gyration (Rg), and solvent-accessible surface area (SASA). These findings support a non-classical mechanism of structural toxicity, wherein NACs exert their effects by disrupting protein stability rather than acting as classical enzyme inhibitors. This study suggests a potential mechanism by which environmental NACs may contribute to fibrotic progression by disrupting the structural stability of BCL2L1 and reshaping the immune microenvironment. Our findings elucidate a potential molecular association between environmental exposure and fibrosis progression, suggesting that BCL2L1-mediated structural toxicity may serve as a potential biomarker and therapeutic target for pollution-related pulmonary fibrosis.